Correlation of wilms' tumor 1 isoforms with HER2 and ER-α and its oncogenic role in breast cancer

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1333-1342

  Nasomyon, Tapanawan ^a   Samphao, Srila ^a   Sangkhathat, Surasak ^a   Mahattanobon, Somrit ^a   Graidist, Potchanapond ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Breast cancer; ER ; HER2; WT1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; SMALL INTERFERING RNA; WT1 PROTEIN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; ISOPROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURGERY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NEPHROBLASTOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; ER-Α; FEMALE; FOLLOW UP; GENETICS; HER2; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WT1;

BREAST CANCER; ER-Α; HER2; WT1;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84899685890     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Buckler AJ, Pelletier J, Haber DA, Glaser T and Housman DE: Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 11: 1707-1712, 1991.
2. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100: 297-303, 2002.
3. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D and Sukumar S: Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61: 921-925, 2001.
4. Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, Hosen N, Tsuboi A, Kawakami M, Ikegame K, Oka Y, Ogawa H, Noguchi S and Sugiyama H: Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol 34: 74-77, 2004.
5. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, Nezu R, Yoshikawa Y, Inoue Y, Hosen N, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Souda S, Aozasa K, Monden M and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94: 712-717, 2003.
6. Miwa H, Beran M and Saunders GF: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6: 405-409, 1992.
7. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T and Nasu K: WT1 as a new prognosis factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079, 1994.
8. Yang L, Han Y, Saiz FS and Minden MD: A tumor suppressor and oncogene: The WT1 story. Leukemia 21: 868-876, 2007.
9. Nichols KE, Re GG, Yan YX, Garvin AJ and Haber DA: WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 55: 4540-4543, 1995.
10. Scharnhorst V, Eb van der AJ and Jochemsen AG: WT1 proteins: functions in growth and differentiation. Gene 61: 141-161, 2001.
11. Zapata-Benavides P, Tuna M, Lopez-Berestein G and Tari AM: Down-regulation of Wilms' tumor 1 protein inhibit breast cancer proliferation. Biochem Biophys Res Commun 295: 784-790, 2002.
12. Han Y, San-Marina S and Liu J: Transcriptional activation of c- MYC proto-oncogene by WT1 protein. Oncogene 23: 6933-6941, 2004.
13. McCarty G, Awad O and Loeb DM: WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem 286: 43634-43643, 2011.
14. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H and Noguchi S: High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8: 1167-1171, 2002.
15. Wagner N, Panelos J, Massi D and Wagner KD: The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 455: 839-847, 2008.
16. Call KM, Glaser T, Ito CY, Bucker AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C and Housman DE: Isolation and characterization of zinc finger polypeptide gene at the human chromosome11 Wilms' tumor locus. Cell 60: 509-520, 1990.
17. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM and Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88: 9618-9622, 1991.
18. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE and Baldwin AS: WT1 modulates apoptosis by transcriptionally up-regulating the BCL-2 protooncogene. EMBO J 18: 3990-4003, 1999.
19. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, Tamaki H, Sakaguchi N, Shirakata T, Nishida S, Kawakami M, Tsuboi A, Oka Y, Tsujimoto Y and Sugiyama H: Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 25: 4217-4299, 2006.
20. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, Kitamura Y, Miyai S, Jomgeow T, Li Z, Shirakata T, Nishida S, Tsuboi A, Oka Y and Sugiyama H: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 32: 701-711, 2008.
21. Graidist P, Nawakhanitworakul R, Saekoo J, Dechsukhum C and Fujise K: Anti-apoptotic function of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms in breast cancer. Asian Biomed 4: 711-720, 2010.
22. Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist 9: 606-616, 2004.
23. Osborne CK and Schiff R: Estrogen-receptor biology: continuing progress and therapeutic impalications. J Clin Oncol 23: 1616-1622, 2005.
24. Arpino G, Wiechmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
25. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
26. Wang L and Wang ZY: The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF cells. Oncol Rep 23: 1109-1117, 2010.
27. Wang L, Zhang X and Wang ZY: The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Anticancer Res 21: 3637-3642, 2010.
28. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1975.
29. Scarff RW and Torloni H: Histological typing of breast tumors, International histological classification of tumours. World Health Organization 2: 13-20, 1968.
30. Navakanit R, Graidist P, Leeanansaksiri W and Dechsukum C: Growth inhibition of breast cancer cell line MCF-7 by siRNA silencing of Wilm tumor 1 gene. J Med Assoc Thai 90: 2416-2421, 2007.
31. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T and Sugiyama H: Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90: 194-204, 1999.
32. Jelen L, Fevens T and Krzyzak A: Classification of breast cancer malignancy using cytological images of fine-needle aspiration biopsies. Int J Appl Math Comput Sci 18: 75-83, 2008.
33. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Seventh Edition. New York, NY: Springer, 2010.
34. Speirs V, Carder PJ and Lansdown MR: Oestrogen receptor β: How should we measure this? Br J Cancer 87: 688-689, 2002.
35. Hall JM and McDonnell DP: The estrogen receptor β-isoform (ER-β) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578, 1999.
36. Nemere I, Pietras RJ and Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 88: 438-445, 2003.
37. Lee AV and Cui X: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7: 4429-4435, 2001.
38. Klinge CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905-2919, 2001.
39. Sanchez R, Nguyen D, Rocha W, White JH and Mader S: Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24: 244-254, 2002.
40. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331-336, 2004.
41. Klinge CM, Jernigan SC, Smith SL, Tyulmenkov VV and Kulakosky PC: Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha. Mol Cell Endocrinol 174: 151-166, 2001.
42. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F and Salomon DS: Regulation by estrogen through the 5'-flanking region of the transforming growth factor α gene. Mol Endocrinol 5: 1955-1963, 1991.
43. Lee AV, Guler BL, Sun X, Oesterreich S, Zhang QP, Curran EM and Welshons WV: Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signaling and growth in MCF-7 cells. Eur J Cancer 36: 109-110, 2000.
44. Pedram A, Razandi M, Kehrl J and Levin ER: Natriuretic peptides inhibit G protein activation. Mediation through crosstalk between cyclic GMP-dependent protein kinase and regulators of G protein signaling proteins. J Biol Chem 275: 7365-7372, 2000.
45. Razandi M, Pedram A, Park ST and Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712, 2003.
46. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P and Levin ER: Identification of a structural determinant necessary for the localization and function of estrogen receptor at the plasma membrane. Mol Cell Biol 23: 1633-1646, 2003.
47. Caldon CE, Lee CSL, Sutherland RL and Musgrove EA: Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulate proliferation and differentiation. Oncogene 27: 126-138, 2008.
48. Burwell EA, McCarty GP, Simpson LA, Thompson KA and Loeb DM: Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene 26: 3423-3430, 2007.
49. Reizner N, Maor S, Sarfstein R, Abramovitch S, Welshons WV, Curran EM, Lee AV and Werner H: The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor alpha and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol 35: 135-144, 2005.
50. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K and Sugiyama H: Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 94: 259-270, 2006.